Mutations such as G719S, L858R, T790M, G719S/T790M or T790M/L858R can alter the kinase activity of EGFR by disrupting autoinhibitory interactions [1], which are associated with different drug responses from non-small cell lung cancer patients. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.